StockData
Erasca, Inc. logo

Erasca, Inc. (ERAS) stock

ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$13.76−0.13 (-0.94%)

Close on Nov 18, 2026Market cap $4.81BP/E –Yield 0.00%

Erasca operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Erasca's operating income for the twelve months ending Jun 30, 2026 was -$302.68M. For fiscal 2025 it was -$140.91M. The highest annual figure on record is -$109.25M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$140.91M–
FY2024Dec 31, 2024-$179.59M–
FY2023Dec 31, 2023-$141.53M–
FY2022Dec 31, 2022-$247.45M–
FY2021Dec 31, 2021-$124.88M–
FY2020Dec 31, 2020-$109.25M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$47.62M–
Q1 FY2026Mar 31, 2026-$187.91M–
Q4 FY2025Dec 31, 2025-$32.60M–
Q3 FY2025Sep 30, 2025-$34.55M–
Q2 FY2025Jun 30, 2025-$38.13M–
Q1 FY2025Mar 31, 2025-$35.63M–
Q4 FY2024Dec 31, 2024-$35.71M–
Q3 FY2024Sep 30, 2024-$37.24M–
Q2 FY2024Jun 30, 2024-$67.78M–
Q1 FY2024Mar 31, 2024-$38.85M–
Q4 FY2023Dec 31, 2023-$33.87M–
Q3 FY2023Sep 30, 2023-$34.66M–
Q2 FY2023Jun 30, 2023-$35.97M–
Q1 FY2023Mar 31, 2023-$37.03M–
Q4 FY2022Dec 31, 2022-$138.08M–
Q3 FY2022Sep 30, 2022-$36.96M–
Q2 FY2022Jun 30, 2022-$35.91M–
Q1 FY2022Mar 31, 2022-$36.51M–
Q4 FY2021Dec 31, 2021-$31.05M–
Q3 FY2021Sep 30, 2021-$46.04M–
Q2 FY2021Jun 30, 2021-$28.18M–
Q1 FY2021Mar 31, 2021-$19.61M–
Q4 FY2020Dec 31, 2020-$66.97M–
Q3 FY2020Sep 30, 2020-$11.16M–
Q2 FY2020Jun 30, 2020-$7.28M–

More Erasca figures

See a number that looks wrong?